Literature DB >> 955495

Lithocholate metabolism during chenotherapy for gallstone dissolution. 1. Serum levels of sulphated and unsulphated lithocholates.

R N Allan, J L Thistle, A F Hofmann, J A Carter, P Y Yu.   

Abstract

Serum levels of total sulphated and total unsulphated lithocholates were each measured by a specific radioimmunoassay in 66 patients ingesting chenodeoxycholic (chenic) acid for gallstone dissoultion and in 35 gallstone patients ingesting either cholic acid or placebo. No changes occurred in serum lithocholate levels in the control groups. In patients ingesting chenic acid, there was a twofold increase in serum levels of total lithocholate, but the percent sulphation (greater than 75%) remained unchanged during chenotherapy. There was no correlation in the chenic acid treated group between serum lithocholate levels and the proportion of lithocholate in biliary bile acids or changes in serum SGOT. The data suggest that there is effective sulphation of lithocholate in such patients; this may explain the lack of hepatotoxicity observed during ingestion of chenic acid.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 955495      PMCID: PMC1411127          DOI: 10.1136/gut.17.6.405

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  23 in total

1.  IDENTIFICATION OF ALLODEOXYCHOLIC ACID AS THE MAJOR COMPONENT OF GALLSTONES INDUCED IN THE RABBIT BY 5-ALPHA-CHOLESTAN-3-BETA-OL.

Authors:  A F HOFMANN; E H MOSBACH
Journal:  J Biol Chem       Date:  1964-09       Impact factor: 5.157

2.  Toxicity of chenodeoxycholic acid in the nonhuman primate.

Authors:  K P Morrissey; C K McSherry; R L Swarm; W H Nieman; J E Deitrick
Journal:  Surgery       Date:  1975-06       Impact factor: 3.982

3.  Efficacy and specificity of chenodeoxycholic acid therapy for dissolving gallstones.

Authors:  J L Thistle; A F Hofmann
Journal:  N Engl J Med       Date:  1973-09-27       Impact factor: 91.245

4.  Degradation of steroids by intestinal bacteria. II. Enzymes catalysing the oxidoreduction of the 3 alpha-, 7 alpha- and 12 alpha-hydroxyl groups in cholic acid, and the dehydroxylation of the 7-hydroxyl group.

Authors:  V Aries; M J Hill
Journal:  Biochim Biophys Acta       Date:  1970-05-05

5.  An algorithm for monitoring and managing drug hepatotoxicity.

Authors:  A F Hofmann; J L Thistle
Journal:  Gastroenterology       Date:  1974-08       Impact factor: 22.682

Review 6.  Bile acids, liver injury, and liver disease.

Authors:  R H Palmer
Journal:  Arch Intern Med       Date:  1972-10

7.  Influence of primary bile acid feeding on cholesterol metabolism and hepatic function in the rhesus monkey.

Authors:  K H Webster; M C Lancaster; A F Hofmann; D F Wease; A H Baggenstoss
Journal:  Mayo Clin Proc       Date:  1975-03       Impact factor: 7.616

8.  Hepatic toxicity in the rhesus monkey treated with chenodeoxycholic acid for 6 months: biochemical and ultrastructural studies.

Authors:  H Dyrszka; G Salen; F G Zaki; T Chen; E H Mosbach
Journal:  Gastroenterology       Date:  1976-01       Impact factor: 22.682

9.  Effect of oral chenodeoxycholic acid on bile acid kinetics and biliary lipid composition in women with cholelithiasis.

Authors:  R C Danzinger; A F Hofmann; J L Thistle; L J Schoenfield
Journal:  J Clin Invest       Date:  1973-11       Impact factor: 14.808

10.  BILE ACIDS IN INFANTS AND CHILDREN.

Authors:  J R POLEY; J C DOWER; C A OWEN; G B STICKLER
Journal:  J Lab Clin Med       Date:  1964-05
View more
  9 in total

1.  Taurolithocholate inhibits taurocholate uptake by isolated hepatocytes at low concentrations.

Authors:  M Schwenk; L R Schwarz; H Greim
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977-06       Impact factor: 3.000

Review 2.  Ursodeoxycholic acid in the treatment of cholesterol cholelithiasis. Part II.

Authors:  W H Bachrach; A F Hofmann
Journal:  Dig Dis Sci       Date:  1982-09       Impact factor: 3.199

3.  Lithocholate metabolism during chemotherapy for gallstone dissolution. 2. Absorption and sulphation.

Authors:  R N Allan; J L Thistle; A F Hofmann
Journal:  Gut       Date:  1976-06       Impact factor: 23.059

4.  Faecal bile acid loss and bile acid pool size during short-term treatment with ursodeoxycholic and chenodeoxycholic acid in patients with radiolucent gallstones.

Authors:  G Salvioli; R Salati
Journal:  Gut       Date:  1979-08       Impact factor: 23.059

5.  Effect of taurolithocholate on in vivo sulfation and glucuronidation of acetaminophen in rats.

Authors:  R E Galinsky; B Chałasinska
Journal:  Pharm Res       Date:  1988-01       Impact factor: 4.200

6.  Bile acid conjugation in the chimpanzee: effective sulfation of lithocholic acid.

Authors:  M Schwenk; A F Hofmann; G L Carlson; J A Carter; F Coulston; H Greim
Journal:  Arch Toxicol       Date:  1978-04-27       Impact factor: 5.153

7.  Sulfation of lithocholate as a possible modifier of chenodeoxycholic acid-induced elevations of serum transaminase in patients with gallstones.

Authors:  J W Marks; S O Sue; B J Pearlman; G G Bonorris; P Varady; J M Lachin; L J Schoenfield
Journal:  J Clin Invest       Date:  1981-11       Impact factor: 14.808

Review 8.  Chenodeoxycholic acid: a review of its pharmacological properties and therapeutic use.

Authors:  J H Iser; A Sali
Journal:  Drugs       Date:  1981-02       Impact factor: 9.546

9.  Relationship between serum and biliary bile acids as an indicator of chenodeoxycholic and ursodeoxycholic acid-induced hepatotoxicity in the rhesus monkey.

Authors:  F Bazzoli; A Roda; H Fromm; R P Sarva; E Roda; L Barbara
Journal:  Dig Dis Sci       Date:  1982-05       Impact factor: 3.199

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.